NCT07260734Not yet recruiting
AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)
Source: ClinicalTrials.gov · Last updated 3 Dec 2025
Brief summary (registry, in English)
Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut. The proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 6000 (estimated)
- First submitted
- 21 Nov 2025
- Start date
- 1 Dec 2025
- Primary completion date
- 1 Nov 2028
- Lead sponsor
- Imperial College London
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07260734
What you commit to
- Study type: Observational
- Planned participants: 6000
- From 1 Dec 2025 to the primary completion date, 1 Nov 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous oesophageal or gastric resection
Other illness
- History of cancer within three years (other than non-melanoma skin cancers)
Lab values
- Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid
Other
- Co-morbidities preventing breath collection
- Pregnant participants
- Unable or unwilling to provide informed written consent.
Who the study is looking for
- Aged ≥ 18 years old.
- Participants referred from primary care according to the urgent suspected cancer referral guidelines for potential underlying oesophagogastric cancer a for the reference test (described below).
- Willing and able to provide informed written consent to take part in study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.